Serum follistatin in patients with prostate cancer metastatic to the bone

Marilena Crescimanno, Carla Flandina, Giuseppe Badalamenti, Francesca Maria Tumminello, Lorena Incorvaia, Fabio Fulfaro, Gaetano Leto, Lorena Incorvaia, Giuseppe Badalamenti, Maria Vittoria Sepporta, Carla Flandina, Francesca Maria Tumminello, Fabio Fulfaro, Marilena Crescimanno, Gaetano Leto

Risultato della ricerca: Article

19 Citazioni (Scopus)

Abstract

The clinical significance of circulating fol- listatin (FLST), an inhibitor of the multifunctional cytokine activin A (Act A), was investigated in patients with prostate cancer (PCa). The serum concentrations of this molecule were determined by an enzyme-linked immunosorbent assay (ELISA) in PCa patients with (M?) or without (M0) bone metastases, in patients with benign prostate hyperplasia (BPH) and in healthy sub- jects (HS). The effectiveness of FLST in detecting PCa patients with skeletal metastases was determined by the receiver operating characteristic (ROC) curve analysis. Serum FLST was significantly higher in PCa patients than in BPH patients (P = 0.001) or HS (P = 0.011). Conversely, in BPH patients, FLST levels resulted lower than in HS (P = 0.025). In cancer patients the serum concentrations of FLST significantly correlated with the presence of bone metastases (P = 0.0005) or increased PSA levels (P = 0.04). Interestingly, significant differ- ences in the ratio between FLST and Act A serum concentrations (FLST/Act A) were observed between HS and BPH patients (P = 0.001) or PCa patients (P = 0.0005). Finally, ROC curve analysis, highlighted a sound diagnostic performance of FLST in detecting patients (P = 0.0001). However, the diagnostic effectiveness of FLST did not result significantly supe- rior to that of Act A or PSA. These findings suggest that FLST may be regarded as a potential, molecular target in the treatment of metastatic bone disease while its clinical role as soluble marker in the clinical management of PCa patients with bone metastases needs to be better defined.
Lingua originaleEnglish
pagine (da-a)549-555
Numero di pagine7
RivistaCLINICAL & EXPERIMENTAL METASTASIS
Volume27
Stato di pubblicazionePublished - 2010

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cita questo

Crescimanno, M., Flandina, C., Badalamenti, G., Tumminello, F. M., Incorvaia, L., Fulfaro, F., Leto, G., Incorvaia, L., Badalamenti, G., Sepporta, M. V., Flandina, C., Tumminello, F. M., Fulfaro, F., Crescimanno, M., & Leto, G. (2010). Serum follistatin in patients with prostate cancer metastatic to the bone. CLINICAL & EXPERIMENTAL METASTASIS, 27, 549-555.